SGLT2 inhibition represent a very attractive therapeutic option even on the grounds of its demonstrated benefits in non-diabetic HF patients, especially those with HFpEF, a challenging syndrome that until now lacked effective treatments. Here, SLC5A2 is linked to hydrops fetalis.